Treatment of T2DM patients with IL-1 receptor blocker [184, 185] or IL-1β antibodies [186–189] reduced levels of IL-6 and CRP as markers of systemic inflammation, with simultaneous improvement of glycemia and insulin secretion. Here, IL1B is linked to type 2 diabetes mellitus.